Characteristics and the Need for Supplementation Following 0.19mg Fluocinolone Acetonide (FAc) in Diabetic Macular Edema (DME) Patients

Related

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Brolucizumab for the treatment of visual impairment due to diabetic macular edema: 52-week results from the KITE and KESTREL studies

  David M. Brown, MD

  Updates from the Field

  2021

• 

  Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2019